AstraZeneca (AZ) has shared positive results from a late-stage study evaluating Tagrisso (osimertinib) as an additional treatment for certain lung cancer patients. The phase 3 ADAURA trial enrolled ...

SAVANNAH and ORCHARD Phase II trials show the addition of Orpathys or Datroway to Tagrisso upon disease progression demonstrates strong clinical activity New study results presented at the European ...

Patients were treated with TAGRISSO 80mg once daily oral tablets in combination with chemotherapy (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin (AUC5)) every three weeks for four ...

Based on LAURA Phase III trial results which showed patients who took TAGRISSO after CRT had a median progression-free survival of more than 3 years MISSISSAUGA, ON, May 21, 2025 /CNW/ - Health Canada ...

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...

AstraZeneca (AZ) has shared positive late-stage results demonstrating that Tagrisso (osimertinib) achieved a statistically significant improvement in progression-free survival for a subset of lung ...

AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS) for those with first-line locally advanced or metastatic ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...

The approval is based on results from the AURA3 trial, which found an improvement in investigator-assessed progression-free survival with Tagrisso when compared to a platinum-based doublet ...

In LAURA Phase III trial, Tagrisso continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of Orpathys or ...